Macular Degeneration Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Macular Degeneration Treatment Market is Segmented By Type (Wet Macular Degeneration, Dry Macular Degeneration), By Treatment (Drugs, Therapy, Surgery, Others), By End-User (Hospitals, Ambulatory Surgical Centers, Ophthalmic Clinics, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Macular Degeneration Treatment Market Overview

The Global Macular Degeneration Treatment Market reached USD 9.3 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 15.3 billion by 2030. The global macular degeneration treatment market is expected to exhibit a CAGR of 6.6% during the forecast period (2023-2030). The macular degeneration treatment market has experienced significant growth and advancements in recent years.

The market offers various treatment options such as anti-vascular endothelial growth factor (anti-VEGF) drugs, laser therapy, and photodynamic therapy, aimed at slowing down the progression of the disease and preserving vision. Additionally, ongoing research and development activities focused on developing novel therapies and gene therapies hold promising potential for further advancements in the macular degeneration treatment market.

The global macular degeneration treatment market is driven by the factors such as increasing prevalence, increasing demand for therapeutic innovations, rising aging population, increasing awareness and patient education, rising clinical trials for dry macular degeneration drugs, and technological advancements in treatment options.

Macular Degeneration Treatment Market Scope

For more details on this report – Request for Sample 

Macular Degeneration Treatment Market Dynamics

Increasing Demand for Therapeutic Innovations Drives the Growth of the Macular Degeneration Treatment Market

Macular degeneration, a leading cause of vision loss, has propelled extensive research and development efforts aimed at developing novel and more effective treatment options. Therapeutic innovations such as anti-vascular endothelial growth factor (anti-VEGF) drugs, gene therapies, and regenerative medicine have shown promising results in managing and slowing down the progression of the disease. These advancements have generated a surge in demand from patients and healthcare professionals seeking improved treatment outcomes.

Furthermore, regenerative medicine approaches, such as stem cell therapy and retinal tissue engineering, hold significant promise for restoring vision by replacing damaged retinal cells. These innovative therapeutic avenues have generated substantial excitement and investment, driving the growth of the macular degeneration treatment market.

For instance, on August 19, 2022, a University of Toronto research team created a new platform that delivers multiple therapeutic proteins to the body, each at its own independently controlled rate. The innovation could help treat degenerative diseases such as age-related macular degeneration (AMD), the leading cause of vision loss for people over 50.

Rising Clinical Trials for Macular Degeneration Drugs Also Drive the Growth of the Macular Degeneration Treatment Market

There have been limited treatment options for macular degeneration, with no approved therapies to halt or reverse its progression. However, the growing understanding of the underlying mechanisms and the urgent need for effective treatments have spurred extensive research and development activities.

Clinical trials play a crucial role in evaluating the safety and efficacy of new drugs and treatment modalities. The increasing number of clinical trials focused on macular degeneration is indicative of the heightened interest and investment in finding therapeutic solutions. These trials explore various approaches, including complement inhibitors, neuroprotective agents, visual cycle modulators, and regenerative therapies.

For instance, on April 12, 2023, Aviceda Therapeutics, a private clinical-stage biotech company, announced that the U.S. Food and Drug Administration (FDA) has cleared the IND for AVD-104, enabling the company to proceed with initiating Phase 2 clinical trials of its lead intravitreal ocular asset for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration. 

Side Effects Associated with Drugs Will Hamper the Growth of the Market

Many treatment options, such as anti-vascular endothelial growth factor (anti-VEGF) drugs, have shown significant efficacy in managing macular degeneration, they are not without potential adverse effects. In the case of anti-VEGF drugs, which are administered through intravitreal injections, there are potential risks and side effects associated with the procedure itself. These can include infection, retinal detachment, increased intraocular pressure, and inflammation of the eye. 

Although these complications are relatively rare, they can still raise concerns among patients and healthcare professionals, potentially affecting treatment decisions and market growth.

Macular Degeneration Treatment Market Segment Analysis

The global macular degeneration treatment market is segmented based on type, treatment, end-user, and region.

The Wet Macular Degeneration Segment Accounted for Approximately 55.9% of the Macular Degeneration Market Share

Wet macular degeneration is characterized by the growth of abnormal blood vessels beneath the retina, which can lead to severe vision loss if left untreated. This form of macular degeneration requires immediate and aggressive treatment approaches to inhibit the growth of these abnormal blood vessels and preserve vision.

The primary treatment for wet macular degeneration involves the use of anti-vascular endothelial growth factor (anti-VEGF) drugs. These drugs are administered through intravitreal injections and work by blocking the activity of VEGF, a protein that promotes the growth of abnormal blood vessels. Anti-VEGF therapy has shown remarkable efficacy in stabilizing or improving vision in patients with wet macular degeneration.

For instance, on June 10, 2023, Ocular Therapeutix, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced 12-month data from its Phase 1 U.S. clinical trial evaluating OTX-TKI, the Company’s axitinib intravitreal hydrogel implant, for the treatment of wet macular degeneration. OTX-TKI is also being developed for the treatment of diabetic retinopathy and other retinal diseases.

Source: DataM Intelligence Analysis (2023)

Global Macular Degeneration Treatment Market Geographical Penetration

North America Accounted for Approximately 40.4% of the Market Share in 2022, Owing to the Advanced Healthcare Infrastructure and rising aging population

The region's advanced healthcare infrastructure, including well-equipped hospitals, specialized ophthalmology centers, and advanced diagnostic and treatment facilities, contribute to the growth of the market. The availability of these resources enables efficient diagnosis, treatment, and management of macular degeneration, attracting patients seeking high-quality healthcare services.

Moreover, North America has a substantial aging population, which is more prone to macular degeneration. The prevalence of age-related macular degeneration (AMD) increases with advancing age, and as North America has a higher proportion of older adults, the demand for macular degeneration treatment is significant. The rising aging population further fuels market growth in the region.

Source: DataM Intelligence Analysis (2023)

Macular Degeneration Treatment Market Companies 

The major global players in the macular degeneration treatment market include Novartis AG, Regeneron Pharmaceuticals Inc., Genentech USA, Inc., REGENXBIO Inc., Bausch Health Companies Inc., F Hoffmann-La Roche Ltd, Santen Pharmaceutical Co., Ltd., GNH Pharmaceuticals USA LLC, Iveric Bio Inc., and Allergan, Inc.  

COVID-19 Impact on Macular Degeneration Treatment Market

Russia Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global macular degeneration treatment market. If the conflict affects the production or transportation of macular degeneration drugs, medical devices, or other related products, it can lead to supply chain disruptions. This can result in shortages of critical medications or delays in accessing necessary treatments, potentially impacting the availability and affordability of macular degeneration treatments globally.

By Type

• Wet Macular Degeneration 
• Dry Macular Degeneration

By Treatment Type

• Drugs

• Anti-vascular Endothelial Growth Factor
• Others

• Surgery
• Others

By End User

• Hospitals 
• Ophthalmic Clinics
• Ambulatory Surgical Centers
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • The U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• On April 21, 2023, The Janssen Pharmaceutical Companies of Johnson & Johnson announced that five company-sponsored presentations will be featured during the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting in New Orleans from April 23-27, 2023. Janssen presentations will include updates from the Phase 1/2 MGT009 trial for investigational gene therapy botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) in patients with the inherited retinal disease (IRD) X-linked retinitis pigmentosa (XLRP) associated with the retinitis pigmentosa GTPase regulator (RPGR) gene, and pooled safety analysis data from two Phase 1 trials of the investigational gene therapy JNJ-81201887, one trial in patients with geographic atrophy (GA), a late-stage and severe form of age-related macular degeneration (AMD) and one trial in wet AMD.
• On February 27, 2023, EyePoint Pharmaceuticals, Inc., a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, and Rallybio Corporation, a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, announced a research collaboration. The partnership will evaluate the sustained delivery of Rallybio’s inhibitor of complement component 5 (C5) using EyePoint’s proprietary Durasert technology for sustained intraocular drug delivery. The initial focus will be on geographic atrophy, an advanced form of age-related macular degeneration that leads to irreversible vision loss.

Why Purchase the Report?

• To visualize the global macular degeneration treatment market segmentation based on type, treatment, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of macular degeneration treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global macular degeneration treatment market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

For more Pharmaceuticals related reports, please click here